Skip directly to site content
Are You Still There?
Due to inactivity, you will be signed out in two minutes unless you click 'Continue'.

Panel:   Multi-site Gram-negative Surveillance Initiative (MuGSI) - (ESBL)
AR Bank # 1017 Escherichia coli
Study ID: ESBL-08

Biosample Accession #: SAMN28235841


Collection Year:
MLST: 167(Achtman), 877(Pasteur)

MICs obtained by broth microdilution. Modal MIC is reported.

MIC results for each antimicrobial agent for an isolate may commonly be ± 1 log2 (doubling dilution) different than what is posted on the FDA & CDC AR Bank website because this is the normal technical variability of antimicrobial susceptibility testing (see J. H. Jorgensen. 1993. J Clin Microbiol. Vol 31[11]: 2841-2844).

Panel:  Multi-site Gram-negative Surveillance Initiative (MuGSI) - (ESBL)

MIC (μg/ml) Results and Interpretation
Drug MIC (μg/ml) INT
Amikacin 8I
Ampicillin >32R
Ampicillin/sulbactam 132R
Aztreonam 64R
Cefazolin >8R
Cefepime >32R
Cefotaxime >64R
Cefotaxime/clavulanic acid 1<=0.25---
Cefoxitin 8S
Ceftazidime 32R
Ceftazidime/avibactam 1<=0.5S
Ceftazidime/clavulanic acid 1<=0.5---
Ceftolozane/tazobactam 1<=0.5S
Ceftriaxone >32R
Ciprofloxacin >8R
Colistin 40.5I
Doripenem <=0.12S
Ertapenem <=0.12S
Gentamicin 0.5S
Imipenem <=0.5S
Imipenem+chelators 2<=0.25---
Levofloxacin 8R
Meropenem <=0.12S
Meropenem-vaborbactam 1<=0.5S
Minocycline <=4S
Piperacillin/tazobactam 18S
Tetracycline >32R
Tigecycline 3<=0.5S
Tobramycin 8R
Trimethoprim/sulfamethoxazole 1<=0.5S
SDD (Susceptible Dose Dependent)
MICs obtained by broth microdilution. Modal MIC is reported
S – I –R Interpretation (INT) derived from CLSI 2023 M100 S33

1 Reflects MIC of first component
2 Screen for metallo-beta-lactamase production [Rasheed et al. Emerging Infectious Diseases. 2013. 19(6):870-878]
3 Based on FDA break points
4 Clinical and PK/PD data demonstrate colistin has limited clinical efficacy, even if an intermediate result is obtained. Alternative agents are strongly preferred. Colistin should be used in combination with one or more active antimicrobial agents. Consultation with an infectious disease specialist is recommended.
Device manufacturers and users of FDA cleared devices shall consult the FDA’s Antibacterial Susceptibility Test Interpretive Criteria       website for breakpoints recognized or recommended by FDA, and for information regarding FDA exceptions or additions to the applicable, recognized consensus standard.
Molecular Mechanisms of Resistance
Aminoglycoside aac(6')-Ib-cr, aph(3')-Ib, aph(6)-Id
Beta-lactam CTX-M-15, OXA-1
Phenicols/Bicyclomycins catB4
Sulfonamides sul2
Tetracyclines tet(A), tet(R)
The resistance mechanisms listed were identified by analysis of whole genome sequence using ARG-ANNOT and ResFinder databases accessed on 2018/06/08. This analysis does not include mutations that may result in antibiotic resistance or resistance determinants added to newer versions of the ResFinder database or other antimicrobial resistance gene databases. For resistance determinant detection, 99-100% sequence identity and 100% sequence coverage was used. Biosample accession numbers have been provided so that users can analyze the data on their own if so desired. MLST Reported as determined by Torsten Seemann's MLST program. For Enterobacterales, the Pasteur MLST schemes are used except for E. coli for which both the Pasteur and Achtman schemes are reported. SUB=novel MLST identified.
Medium: Trypticase Soy Agar with 5% Sheep Blood (BAP)

Temperature: 35°C
Atmosphere: Aerobic


Remove the sample vial to a container with dry ice or a freezer block. Keep vial on ice or block. (Do not let vial content thaw)

Open vial aseptically to avoid contamination

Using a sterile loop, remove a small amount of frozen isolate from the top of the vial

Aseptically transfer the loop to BAP

Use streak plate method to isolate single colonies

Incubate inverted plate at 35°C ± 2°C for 18-24 hrs.

Storage Temperature & Biosafety

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the current publication of 'BioSafety in Microbiological and Biomedical Laboratories' from the U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, and National Institutes of Health.

This product is sent with the condition that you are responsible for its safe storage, handling, and use. All materials are the property of the Centers for Disease Control and Prevention (CDC) and have been made available on behalf of the Food and Drug Administration (FDA). This material is not for use in human subjects and may not be redistributed. While CDC uses reasonable efforts to include accurate and up-to-date information on this product sheet, CDC makes no warranties or representations as to its accuracy. CDC is not liable for damages arising from the misidentification or misrepresentation of cultures. Please refer to the Standard Letter Agreement (SLA) for further details regarding the use of this product.
Isolate History
Date Action Performed
09/14/23INT was updated with a new value for Amikacin: from 'S' to 'I'
04/12/23INT was updated with a new value for Tobramycin: from 'I' to 'R'
01/24/23INT was updated with a new value for Cefazolin: from '---' to 'R'
01/24/23MIC was updated with a new value for Cefazolin: from '---' to '>8'
01/24/23Drug was added: Cefazolin
Top of Page